Neurodegenerative disorders like Parkinson＇s disease （PD） or atypi- cal Parkinsonian syndromes including the different synucleinopa- thies and tauopathies are an important burden for patients, rela- tives, care pro...Neurodegenerative disorders like Parkinson＇s disease （PD） or atypi- cal Parkinsonian syndromes including the different synucleinopa- thies and tauopathies are an important burden for patients, rela- tives, care providers and incur mounting costs for the health care system in our aging society.展开更多
The evaluation of such novel therapies for acute spinal cord injury in clinical trials is extremely challenging.Our current dependence upon the clinical assessment of neurologic impairment renders many acute SCI patie...The evaluation of such novel therapies for acute spinal cord injury in clinical trials is extremely challenging.Our current dependence upon the clinical assessment of neurologic impairment renders many acute SCI patients ineligible for trials because they are not examinable.Furthermore,the difficulty in predicting neurologic recovery based on the early clinical assessment forces investigators to recruit large cohorts to have sufficient power.Biomarkers that objectively classify injury severity and better predict neurologic outcome would be valuable tools for translational research.As such,the objective of the present review was to describe some of the translational challenges in acute spinal cord injury research and examine the potential utility of neurochemical biomarkers found within cerebrospinal fluid and blood.We focus on published efforts to establish biological markers for accurately classifying injury severity and precisely predict neurological outcome.展开更多
基金funded by the TRANSMED Kolleg Gottingen,which was supported by the Ministerium für Wissenschaft und Kultur,Niedersachsenfunded by the DFG-Center for Nanoscale Microscopy and Molecular Physiology of the Brain(CNMPB),Gottingen,Germany
文摘Neurodegenerative disorders like Parkinson＇s disease （PD） or atypi- cal Parkinsonian syndromes including the different synucleinopa- thies and tauopathies are an important burden for patients, rela- tives, care providers and incur mounting costs for the health care system in our aging society.
基金provided by the Rick Hansen InstituteMichael Smith Foundation for Health Research+1 种基金Craig Neilsen Foundationsupported by MITACS
文摘The evaluation of such novel therapies for acute spinal cord injury in clinical trials is extremely challenging.Our current dependence upon the clinical assessment of neurologic impairment renders many acute SCI patients ineligible for trials because they are not examinable.Furthermore,the difficulty in predicting neurologic recovery based on the early clinical assessment forces investigators to recruit large cohorts to have sufficient power.Biomarkers that objectively classify injury severity and better predict neurologic outcome would be valuable tools for translational research.As such,the objective of the present review was to describe some of the translational challenges in acute spinal cord injury research and examine the potential utility of neurochemical biomarkers found within cerebrospinal fluid and blood.We focus on published efforts to establish biological markers for accurately classifying injury severity and precisely predict neurological outcome.
